When I catch up on a call with Ochre Bio co-founder and chief executive Jack O’Meara, he is awaiting his next connection while returning from Boston on a three-flight journey via the Azores to get back to the UK. Such is the life of a start-up CEO when travel plans go awry. It’s been a week or so since he and his teams in New York, Oxford and Taiwan celebrated a potential billion-dollar partnership deal to develop new regenerative treatments for advanced liver disease with German pharma giant Boehringer Ingelheim.  Headquartered on a bank of the Rhine in Germany’s midwest,…

Want to read the full story?

Unlock this article – and everything else on The Currency – with an annual membership and receive a free Samsonite Upscape suitcase, retailing at €235, delivered to your door.

Subscribe

Cancel at any time.

Are you already a member? .